Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343615 | 0.87 | — | — | |
| SCHEMBL2993374 | 0.83 | CHRM2 (0.34) | — | |
| SCHEMBL12465180 | 0.78 | — | — | |
| SCHEMBL15233748 | 0.77 | CHRM3 (0.31) | CHRM3 | |
| SCHEMBL17187563 | 0.77 | — | — | |
| SCHEMBL3281966 | 0.77 | CHRM2 (0.36) | — | |
| SCHEMBL7541983 | 0.76 | KMT2A (0.36) | CHRM3 | |
| SCHEMBL16196858 | 0.76 | — | — | |
| SCHEMBL3340436 | 0.75 | — | — | |
| SCHEMBL3340432 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786308-B2 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | claimed |
| US-20100152176-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-17 | — | — | US | claimed |
| US-7696201-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | claimed |
| EP-2051712-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmceuticals Incorporated (US) | 2009-04-29 | — | — | EP | claimed |
| US-20080176843-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-24 | — | — | US | claimed |
| US-20080090826-A9 | Muscarinic modulators | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2008-04-17 | — | — | US | claimed |
| WO-2008021375-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-21 | — | — | WO | claimed |
| EP-1863490-A2 | MUSCARINIC MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2007-12-12 | — | — | EP | claimed |
| EP-1817036-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | claimed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | claimed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | claimed |
| WO-2006105035-A2 | MUSCARINIC MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-05 | — | — | WO | claimed |
| WO-2006058303-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | claimed |
| EP-2162429-B1 | HALOGEN-CONTAINING ORGANOSULFUR COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-101790511-B | Halogen-containing organosulfur compounds and uses thereof | SUMITOMO CHEMICAL CO | 2013-12-11 | — | — | CN | disclosed |
| US-8247596-B2 | Halogen-containing organosulfur compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | disclosed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | disclosed |
| WO-2006105035-A2 | MUSCARINIC MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006058303-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054911-A1 | Muscarinic modulators | CHRM3, CHRM5, CHRM4 | CHRM3 1/4885 |
| US-20060270653-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885 |
| US-20080176843-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885 |
| US-20100152176-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885 |
| US-20080090826-A9 | Muscarinic modulators | CHRM3, CHRM5, CHRM4 | CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.